COMBINATION CONTAINING NEW DERIVATIVE 3-(4-(BENZYLOXY)PHENYL)HEX-4-IN-ACID AND OTHER ACTIVE INGREDIENT TO ACTIVATE G-PROTEIN 40 OF THE RECEPTOR ENZYME Russian patent published in 2019 - IPC A61K31/357 A61K31/435 A61K31/4035 A61K31/47 A61K31/496 C07D317/72 C07D213/55 C07D221/04 C07D241/04 C07D217/04 C07D209/44 A61K31/00 A61P3/10 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: present invention relates to the pharmaceutical combination for activating the G-protein 40 receptor enzyme (GPR40), which contains a novel derivative 3-(4-(benzyloxy)phenyl)hex-4-ionic acid and the second active ingredient, which is selected from the group consisting of drugs based on dipeptidylpeptidase-4 inhibitors (DPPIV), based on sulfonylureas, based on thiazolidinedione (TZD) , based on the biguanide and on the basis of the sodium/glucose inhibitor of cotransporter 2 (SGLT2). Novel 3-(4-(benzyloxy)phenyl)hex-4-ionic acid derivative is preferably sodium (S)-3-(4-(3-((4-(4-methoxyphenyl)piperazin-1-yl))methyl)benzyloxy)phenyl)hex-4-inoate.

EFFECT: use of a combination of the present invention can provide for a significantly superior effect of reducing blood sugar in various animal models of diabetic diseases, and the combination of the present invention may favorably be used to prevent or treat metabolic disorders such as obesity, type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance syndrome, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and X syndrome.

5 cl, 11 dwg, 16 tbl